These results indicate that IRAKM kinase activity contributes to HFD-induced obesity, which provides the proof of concept data for IRAKM to be pursued as a drug target for treating obesity in the future. The gene discussed is IRAK3; the disease is obesity due to melanocortin 4 receptor deficiency.